While I don't know the 3 different sources to which you refer, it is probably short interest at work with the news outlets...happens all of the time. I would love it when this stock would dip on fears that the market was going entirely to Avastin....it was pure manipulation and scare tactics by the hedge funds to cover their shorts...which presented an opportunity to add. I don't think 3 articles citing Zack's will have any material effect on REGN - but if they do, consider it a buying opportunity.
I wasn't questioning Zack's methodology. I'm questioning why their negative bent on regn has appeared three days in a row. When upgrades have been reported for regn, it's one and done. You don't see repetitive headlines for days highlighting the same upgrade. That's why I was disturbed by the latest report Friday evening. Over the top.
You are a 1000% correct Venture. I read the Zack's analyst report on REGN last night and ALL it references is EYELEA and most recent earnings that missed because of increased expenses. There was little, if any, reference to the pipeline.
Regeneron, "REGN" Will be presenting at FOUR Conference's
1. IR Call on New DRUG ALIROCUMAB On 9-2AMET
2. 9-3 4PMET Baird Healthcare Conference
3. 9-4 8:45AMET CITI'S Annual Biotech Conference
4. 9-8 8:45AMET Morgan Stanly Global Healthcare Conference
This is very Bullish, as REGN Would not be speaking at all these Conference's, if
they were not very bullish on the Phase III Results on ALIROCUMAB, And also on the
rest of there Drugs And there entire Busines!!! Should be a very Interesting Two Weeks!!!
Zacks' approach is to cover all stocks. However, Zacks coverage is often so superficial that it is irrelevant. Zacks is weak in recognizing the effects of change, even in the near future. If you follow Zacks advice for a while you will notice this. The see only what is in the rear-view mirror.
The REGN stock price depends mostly on how its drugs perform in ongoing clinical trials. Zacks "analysis" failed to recognize this. It was based only on past sales figures. Zacks' approach may work for companies whose products change little, but it doesn't apply to REGN.
Should be a very Interesting week as "REGN" Not only has the Results but also 3 Presentations
During the week, they Obviously have a lot of positives to Speak About!!!
Should be a fun week!
Oh they are so transparent. It doesn't matter what they say because it so obvious that they are just a mouthpiece for the some short position. LOL
Third time in the last three days that a negative article from Zach's has been highlighted on this site. Seems that some short or fund is trying to poison the atmosphere here.
So basically the Chairman of Board owns over 640,000 REGN shares ,,,yesterday he cashed out 300,000 plus stock options and kept 150,000 shares with a purchase at $351.. The half he sold was for tax purposes. Good sign ; he didnt sell all 300,000 options on cash out.
They did the same thing in May, then in June, and now again in August. LOL Just Google, you will see. They have no understanding of Biotech.. They should be embarrassed by their ignorance, but doesn't seem to keep them from publishing the same worthless information. Kind of destroys their brand. Thats whats more surprising to me, they do good in other areas, but continue to try to comment on an area they clearly have no understanding of, BIOTECH.